InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | 2026-03-20 | PAGANELLI JOHN A | Director | Purchase | 10.0K | $1.14 | $11K | 394.3K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | $79.7M+3.0% | $77.4M-57.2% | $180.7M+70.9% | $105.7M+309.1% | $25.8M |
| Cost of Goods and Services Sold | $93.6M+1.2% | $92.5M-7.0% | $99.5M+12.6% | $88.4M-2.8% | $91.0M |
| Selling, general and administrative | $223.0M-26.7% | $304.2M+1.2% | $300.6M-19.4% | $372.7M-20.5% | $468.9M |
| Research and development | $124.0M+17.9% | $105.2M+17.4% | $89.6M+21.3% | $73.9M-3.9% | $76.8M |
| Contingent consideration | $0 | $0+100.0% | -$1.0M+21.0% | -$1.3M+23.0% | -$1.7M |
| Amortization of intangible assets | $77.9M-5.7% | $82.6M-3.9% | $86.0M-2.0% | $87.8M+74.6% | $50.3M |
| Gain on sale of assets | -$101.6M+16.4% | -$121.5M | $0+100.0% | -$18.6M+41.1% | -$31.5M |
| Total costs and expenses | $724.3M-16.3% | $865.2M-15.2% | $1.02B-17.1% | $1.23B-29.9% | $1.76B |
| Operating loss | -$117.4M+22.8% | -$152.1M+3.2% | -$157.0M+30.6% | -$226.3M | — |
| Interest income | $14.8M+75.8% | $8.4M+111.5% | $4.0M+101.1% | $2.0M+6975.0% | $28K |
| Interest expense | -$108.5M-128.5% | -$47.5M-251.4% | -$13.5M-12.0% | -$12.1M+36.1% | -$18.9M |
| Fair value changes of derivative instruments, net | -$429K+98.4% | -$26.2M-3249.7% | -$781K-220.3% | $649K-23.3% | $846K |
| Other income (expense), net | -$124.0M-187.5% | $141.7M+619.1% | -$27.3M+83.5% | -$165.3M-1019.0% | -$14.8M |
| Other income (expense), net | -$124.0M-187.5% | $141.7M+619.1% | -$27.3M+83.5% | -$165.3M-1019.0% | -$14.8M |
| Loss before income taxes and investment losses | -$241.4M-2229.3% | -$10.4M+94.4% | -$184.3M+52.9% | -$391.5M-2691.6% | -$14.0M |
| Income tax benefit (provision) | $15.7M+136.7% | -$42.8M-865.6% | -$4.4M | — | -$15.5M |
| Net loss before investment losses | -$225.7M-324.1% | -$53.2M+71.8% | -$188.8M+42.5% | -$328.0M-1011.4% | -$29.5M |
| Loss from investments in investees | -$29K-61.1% | -$18K+83.2% | -$107K+72.1% | -$383K+39.1% | -$629K |
| Net loss | -$225.7M-324.0% | -$53.2M+71.8% | -$188.9M+42.5% | -$328.4M-989.5% | -$30.1M |
| Loss per share Basic | -$300-275.0% | -$80+68.0% | -$250 | — | — |
| Loss per share diluted | -$300-275.0% | -$80+68.0% | -$250 | — | — |
| Weighted average number of common shares outstanding, basic | $751.13B+8.2% | $694.02B-7.7% | $751.77B | — | — |
| Weighted average number of common shares outstanding, diluted | $751.13B+8.2% | $694.02B-7.7% | $751.77B | — | — |
| Service [Member] | |||||
| Revenues | $79.7M+3.0% | $77.4M-57.2% | $180.7M+70.9% | $105.7M+309.1% | $25.8M |
| Cost of Goods and Services Sold | $93.6M+1.2% | $92.5M-7.0% | $99.5M+12.6% | $88.4M-2.8% | $91.0M |
| Product [Member] | |||||
| Revenues | $79.7M+3.0% | $77.4M-57.2% | $180.7M+70.9% | $105.7M+309.1% | $25.8M |
| Cost of Goods and Services Sold | $93.6M+1.2% | $92.5M-7.0% | $99.5M+12.6% | $88.4M-2.8% | $91.0M |
| Transfer of Intellectual Property and Other [Member] | |||||
| Revenues | $79.7M+3.0% | $77.4M-57.2% | $180.7M+70.9% | $105.7M+309.1% | $25.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y